The analysis and dissemination of adverse reaction information for investigational drugs is described for an international pharmaceutical firm. Procedures are detailed which facilitate compliance with often conflicting international requirements for promptly reporting fatal or serious adverse reactions. Procedures include maintaining investigator's brochure-derived adverse experience listings, using FAX machines, each programmed to send information to up to 200 clinical investigators and other selected sites, and circulating reports internally using a local area network
21 Code of Federal Regulations §312.32 IND Safety Reports, §312.33 Annual Reports. U.S. Government Printing Office, Washington, D.C.
2.
CurranCFBawaO.Implementation of a worldwide drug safety surveillance system. Drug Inf J.1990;24(3):605–614.
3.
BernJLBreckenridgeAMMannRDRawlinsMD.Review of yellow cards (1986): Report to the Committee on the Safety of Medicines. Br J Clin Pharmacol1988;26:679–689.
4.
21 CFR Parts 312, 314, 511, adn 514 New Drug, Antibiotic, and Biologic, Drug Product Regulations; Final Rule. V. Comments on the Proposed Rule. Comment 81. Federal Register March 18, 1987;5253:8816.
5.
FlanneryEJ.Reporting foreign ADRs and ADRs in Phase IV studies, and the significance of causality assessment. Food Drug Cosmetic Law J.1991;46(1):43–57.
